RecruitingPhase 2ACTRN12610000291088

effect of alpha lipoic acid on cardiac autonomic function and platelet reactivity in type I diabetes

In patients with type I diabetes is alpha lipoic acid better than placebo for improvement of cardiac autonomic function and reduction of platelet reactivity?


Sponsor

Catholic University

Enrollment

60 participants

Start Date

Dec 1, 2009

Study Type

Interventional

Conditions

Summary

The present randomized study will evaluate the effect of alpha lipoic acid compared to placebo on cardiac autonomic function and platelet reactivity in type I diabetic patients


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing whether a supplement called alpha lipoic acid — a natural antioxidant — can improve heart nerve function and reduce abnormal platelet activity (clotting cells) in people with type 1 diabetes. Diabetes can damage nerves over time, including those that control the heart. Alpha lipoic acid may protect against this damage. Participants will receive either the supplement or a placebo (inactive pill) to compare results. You may be eligible if: - You have type 1 diabetes - You are between 18 and 85 years old You may NOT be eligible if: - You have had a heart attack or have cardiac ischemia (reduced blood flow to the heart) - You have an active inflammatory disease - You have a blood cancer or other blood disorder Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

alpha lipoic acid dose: 800 mg once per day duration of administration: 4 weeks mode of administration: oral capsules

alpha lipoic acid dose: 800 mg once per day duration of administration: 4 weeks mode of administration: oral capsules


Locations(1)

Rome, Italy

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000291088